Agomab Therapeutics(AGMB)
Belgium - Antwerpen
BiotechnologyFocus: Agonistic monoclonal antibody molecules
Agomab Therapeutics is a life sciences company focused on Agonistic monoclonal antibody molecules.
UnknownImmunology
Funding Stage
PUBLIC
Open Jobs
4
Pipeline & Clinical Trials
AGMB-129
Fibrostenotic Crohn's DiseaseClinical Trials (1)
NCT07118878A Multiple Ascending Dose Study With AGMB-129 in Healthy Participants
Phase 1AGMB-129
Healthy VolunteersClinical Trials (1)
NCT06397508Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants
Phase 1ORG-129
Healthy VolunteersClinical Trials (1)
NCT04933565First in Human Study of ORG-129 in Healthy Volunteers
Phase 1AGMB-447
IPFClinical Trials (1)
NCT06181370Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF
Phase 1AGMB-129
Healthy VolunteersClinical Trials (1)
NCT05937386Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants
Phase 1AGMB-129
Fibrostenotic Crohn's DiseaseClinical Trials (1)
NCT05843578STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease
Phase 2Open Jobs (4)
Interview Prep Quick Facts
Portfolio: 6 clinical trials
Open Roles: 4 active jobs